Subscribe To
Xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered,
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and devel...
October 31, 2023, 9:15 am
xtx’s profit from uk operations surges above £1 billion in 2022
Global algorithmic trading firm, xtx Markets, recorded a massive leap in net profit from its UK entitie...
July 17, 2023, 3:36 pm
xtx markets sponsors oxford scholarship, ukraine’s math olympiad team
xtx Markets, a global algorithmic trading firm, has continued its charitable support for mathematics ed...
May 12, 2023, 5:41 pm
Xilio therapeutics announces pipeline and business updates and first quarter 2023 financial results
Initiated Phase 2 clinical trial for xtx202, a tumor-activated IL-2 Anticipate reporting preliminary Ph...
May 9, 2023, 11:30 am
xtx markets promotes dr. hans buehler to co-ceo
xtx Markets, a London-based multi-asset market maker, has promoted Dr Hans Buehler to the position o...
March 31, 2023, 10:00 am
Xilio therapeutics to host live virtual program spotlighting xtx301, a tumor-activated il-12
WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-o...
November 23, 2022, 12:30 pm